Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|June 8, 2015
Top Five Pharma CEO Paypackets Total More Than $100M
Author(s)News Update
June 8, 2015.
Advertisement
Looking at aggregated data from The New York Times, which used filings from the Securities and Exchange Commission to compute CEO compensation,
Motley Fool lists the five best-paid pharma CEOs as
- Lamverto Andriotti, BMS: $26.1 million
- Kenneth Frazier, Merck: $21.4 million
- Alex Gorksy, J&J: 20.4 million
- Ian Read, Pfizer: $18 million
- Richard Gonzalez, AbbVie: $17 million.
The key question, the reports asks, is "
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Advertisement
Advertisement
Trending on PharmExec
1
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
2
FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer
3
How Changes in a Tumor Have a Significant Impact on Treatment Options
4
The US Drug-Pricing Reset: Competing on Net Value
5